Jaundice resident survival guide: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
<div style="width: 1px; height: 1px; background-color: #999999; position: fixed; top: 10px; left: 10px"></div> | <div style="width: 1px; height: 1px; background-color: #999999; position: fixed; top: 10px; left: 10px"></div> | ||
<div style="width: 90%; -webkit-user-select: none;"> | <div style="width: 90%; -webkit-user-select: none;"> | ||
{| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 5%; background: #A8A8A8; position: fixed; top: 250px; right: 20px; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0"; | {| class="infobox" style="margin: 0 0 0 0; border: 0; float: right; width: 5%; background: #A8A8A8; position: fixed; top: 250px; right: 20px; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0" ; | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #A8A8A8;" align=center| {{fontcolor|#2B3B44|Jaundice<BR>Resident Survival Guide}} | ! style="padding: 0 5px; font-size: 80%; background: #A8A8A8;" align="center" |{{fontcolor|#2B3B44|Jaundice<BR>Resident Survival Guide}} | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Overview|Overview]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align="left" |[[{{PAGENAME}}#Overview|Overview]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Causes|Causes]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align="left" |[[{{PAGENAME}}#Causes|Causes]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Complete Diagnostic Approach|Diagnosis]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align="left" |[[{{PAGENAME}}#Complete Diagnostic Approach|Diagnosis]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Treatment|Treatment]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align="left" |[[{{PAGENAME}}#Treatment|Treatment]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Do's|Do's]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align="left" |[[{{PAGENAME}}#Do's|Do's]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Don'ts|Don'ts]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC; border-radius: 5px 5px 5px 5px;" align="left" |[[{{PAGENAME}}#Don'ts|Don'ts]] | ||
|} | |} | ||
__NOTOC__ | __NOTOC__ | ||
{{WikiDoc CMG}}; {{AE}} {{ROM}} | {{WikiDoc CMG}}; {{AE}} {{ROM}} | ||
Line 28: | Line 29: | ||
===Life Threatening Causes=== | ===Life Threatening Causes=== | ||
Life-threatening causes include [[conditions]] that may result in death or permanent disability within 24 hours if left untreated. | Life-threatening causes include [[conditions]] that may result in death or permanent disability within 24 hours if left untreated. | ||
* [[Ascending cholangitis]] | |||
* [[Sepsis]] | *[[Ascending cholangitis]] | ||
* Acute [[liver failure]] (the combination of jaundice with [[hepatic encephalopathy]]) | *[[Sepsis]] | ||
*Acute [[liver failure]] (the combination of jaundice with [[hepatic encephalopathy]]) | |||
===Common Causes=== | ===Common Causes=== | ||
''' Common [[causes]] of acute Jaundice'''<ref name="WarnerWilkinson2017">{{cite journal|last1=Warner|first1=Ben|last2=Wilkinson|first2=Mark|title=Acute jaundice|year=2017|pages=150–154|doi=10.1002/9781119389613.ch23}}</ref> | ''' Common [[causes]] of acute Jaundice'''<ref name="WarnerWilkinson2017">{{cite journal|last1=Warner|first1=Ben|last2=Wilkinson|first2=Mark|title=Acute jaundice|year=2017|pages=150–154|doi=10.1002/9781119389613.ch23}}</ref> | ||
* [[Gilbert syndrome]] | |||
* [[Alcoholic hepatitis]] | *[[Gilbert syndrome]] | ||
* [[Viral hepatitis]] | *[[Alcoholic hepatitis]] | ||
* Obstructive Jaundice due to [[choledocholithiasis]] or [[malignancy]] | *[[Viral hepatitis]] | ||
* Decompensated [[chronic liver disease]] | *Obstructive Jaundice due to [[choledocholithiasis]] or [[malignancy]] | ||
*Decompensated [[chronic liver disease]] | |||
''' Common [[causes]] of chronic progressive jaundice''' | ''' Common [[causes]] of chronic progressive jaundice''' | ||
* [[Cirrhosis]] | |||
* [[Pancreatic cancer]] | *[[Cirrhosis]] | ||
*[[Pancreatic cancer]] | |||
==Diagnosis== | ==Diagnosis== | ||
Line 132: | Line 137: | ||
{{familytree | K01 | | K02 | | K03 | | K04 | | | | |K01=Start workup of [[hemolytic anemia]] with [[blood]] smear & coombs test|K02=❑ [[Gilbert syndrome]]<br>❑ [[Crigler-Najjar]] type I,II|K03=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Additional work-up for specific [[diseases]]'''<div class="mw-collapsible mw-collapsed">[[Viral hepatitis]] serology(e.g. [[HAV]],[[HBV]],[[HCV]])<BR>Toxicology screen<br>[[Acetaminophen]] level<br>[[Cereuloplasmin]] if patient<40 years of age<br>[[Autoantibodies]] ([[ANA]],Anti-sm,LKM,...)<br>[[Ferritin]] & [[TIBC]]<br>[[HbA1c]]<br>[[Pregnancy]] test<br>a1-antitrypsin<br>❑Consider work-up for rare cases<br>[[Liver]] [[biopsy]] if results negative|K04=[[Ultrasound]] }} | {{familytree | K01 | | K02 | | K03 | | K04 | | | | |K01=Start workup of [[hemolytic anemia]] with [[blood]] smear & coombs test|K02=❑ [[Gilbert syndrome]]<br>❑ [[Crigler-Najjar]] type I,II|K03=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Additional work-up for specific [[diseases]]'''<div class="mw-collapsible mw-collapsed">[[Viral hepatitis]] serology(e.g. [[HAV]],[[HBV]],[[HCV]])<BR>Toxicology screen<br>[[Acetaminophen]] level<br>[[Cereuloplasmin]] if patient<40 years of age<br>[[Autoantibodies]] ([[ANA]],Anti-sm,LKM,...)<br>[[Ferritin]] & [[TIBC]]<br>[[HbA1c]]<br>[[Pregnancy]] test<br>a1-antitrypsin<br>❑Consider work-up for rare cases<br>[[Liver]] [[biopsy]] if results negative|K04=[[Ultrasound]] }} | ||
{{familytree | |!| | | | | | |!| | | |,|-|^|-|-|.|}} | {{familytree | |!| | | | | | |!| | | |,|-|^|-|-|.|}} | ||
{{familytree | M01 | | | | | | M02 | |M03 || M04| | | | |M01=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Consider following based on the results:'''<div class="mw-collapsible mw-collapsed">❑ [[Sickle cell disease]]<br>❑ [[Hereditary spherocytosis]]<br>❑ [[G6PD deficiency]]<br>❑ [[Medications]] effect( Rifampicin, Probencid)<br>❑ Immune-mediated hemolysis|M02=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Consider following based on the results:'''<div class="mw-collapsible mw-collapsed">❑ [[Viral]] [[hepatitis]]<br>❑ NAFLD (Non-alcoholic liver disease)<br>❑ ppAlcoholic liver disease]]<br>❑ Metabolic/genetic [[diseases]]<br>[[Hereditary hemochromatosis]]<br>[[Wilson's disease]]<br>[[Alpha-1 antitrypsin deficiency]]<br>❑ Drug-induced and supplemental-induced injury<br>[[Acetaminophen]], kavakava, Vinyl cholride<br>❑ [[Pregnancy]]<br>[[AFLP]],[[HELLP syndrome]]<br>❑ [[Autoimmune hepatitis]]<br>❑ [[Ischemic]] [[hepatitis]]|M03=Bile ducts dilated|M04=[[Bile ducts]] not dilated }} | {{familytree | M01 | | | | | | M02 | |M03 || M04| | | | |M01=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Consider following based on the results:'''<div class="mw-collapsible mw-collapsed">❑ [[Sickle cell disease]]<br>❑ [[Hereditary spherocytosis]]<br>❑ [[G6PD deficiency]]<br>❑ [[Medications]] effect( Rifampicin, Probencid)<br>❑ Immune-mediated hemolysis|M02=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Consider following based on the results:'''<div class="mw-collapsible mw-collapsed">❑ [[Viral]] [[hepatitis]]<br>❑ NAFLD (Non-alcoholic liver disease)<br><nowiki>❑ ppAlcoholic liver disease]]</nowiki><br>❑ Metabolic/genetic [[diseases]]<br>[[Hereditary hemochromatosis]]<br>[[Wilson's disease]]<br>[[Alpha-1 antitrypsin deficiency]]<br>❑ Drug-induced and supplemental-induced injury<br>[[Acetaminophen]], kavakava, Vinyl cholride<br>❑ [[Pregnancy]]<br>[[AFLP]],[[HELLP syndrome]]<br>❑ [[Autoimmune hepatitis]]<br>❑ [[Ischemic]] [[hepatitis]]|M03=Bile ducts dilated|M04=[[Bile ducts]] not dilated }} | ||
{{familytree | | | | | | | | | | | | |!| | | | |!| | | |}} | {{familytree | | | | | | | | | | | | |!| | | | |!| | | |}} | ||
{{familytree | | | | | | | | | | | | | L01 | | L02 | | | | |L01=[[ERCP]]/[[CT]]|L02=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Additional work-up for intrahepatic cholestasis'''<div class="mw-collapsible mw-collapsed">[[Hepatitis]] serology<br>[[Autoantibodies]] for [[autoimmune hepatitis]]<br>Review [[medications]]<br>[[MRCP]]/[[Liver]] [[biopsy]]}} | {{familytree | | | | | | | | | | | | | L01 | | L02 | | | | |L01=[[ERCP]]/[[CT]]|L02=<div style="float: left; text-align: left;width: 20em; padding:1em;">'''Additional work-up for intrahepatic cholestasis'''<div class="mw-collapsible mw-collapsed">[[Hepatitis]] serology<br>[[Autoantibodies]] for [[autoimmune hepatitis]]<br>Review [[medications]]<br>[[MRCP]]/[[Liver]] [[biopsy]]}} | ||
Line 146: | Line 151: | ||
<div class="mw-collapsible mw-collapsed"> | <div class="mw-collapsible mw-collapsed"> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
! align="center" style="background: #4479BA; color: #FFFFFF |Type of hyperbilirubinemia | ! align="center" style="background: #4479BA; color: #FFFFFF " |Type of hyperbilirubinemia | ||
! align="center" style="background: #4479BA; color: #FFFFFF |Diagnostic Indicators | ! align="center" style="background: #4479BA; color: #FFFFFF " |Diagnostic Indicators | ||
! align="center" style="background: #4479BA; color: #FFFFFF |Management Recommendations | ! align="center" style="background: #4479BA; color: #FFFFFF " |Management Recommendations | ||
|- | |- | ||
|'''Managment of isolated unconjugated jaundice, hemolytic''' || | |'''Managment of isolated unconjugated jaundice, hemolytic'''|| | ||
* Any history of recent trauma, [[hematoma]] or [[blood transfusion]]<br> | *Any history of recent trauma, [[hematoma]] or [[blood transfusion]]<br> | ||
*Any recent travel <br> | *Any recent travel <br> | ||
*Inquire about medications that can cause [[hemolysis]] | *Inquire about medications that can cause [[hemolysis]] | ||
*Any positive family history of [[hemolytic anemia]] | *Any positive family history of [[hemolytic anemia]] | ||
| | | | ||
* Work-up and detect the cause of [[hemolysis]], if low [[Hb]], High [[LDH]], Low [[haptoglobin]], and [[reticulocytes]] present<br> | *Work-up and detect the cause of [[hemolysis]], if low [[Hb]], High [[LDH]], Low [[haptoglobin]], and [[reticulocytes]] present<br> | ||
* [[G6PD]] deficiency - mostly recover on its own, if progress to [[hemolytic anemia]], oxygen therapy, or blood transfusion may be required. Avoid of precipitants and etiological factors <br> | *[[G6PD]] deficiency - mostly recover on its own, if progress to [[hemolytic anemia]], oxygen therapy, or blood transfusion may be required. Avoid of precipitants and etiological factors <br> | ||
*[[Spherocytosis]]- [[phototherapy]] and/or exchange transfusion for infants, [[Folic acid]] for maintaining [[erythropoiesis]]. Splenectomy is the definitive treatment <br> | *[[Spherocytosis]]- [[phototherapy]] and/or exchange transfusion for infants, [[Folic acid]] for maintaining [[erythropoiesis]]. Splenectomy is the definitive treatment <br> | ||
* [[Sickle cell anemia]]- reduce pain and prevent complications, blood transfusions and supplemental oxygen, as well as a bone marrow transplant.<br> | *[[Sickle cell anemia]]- reduce pain and prevent complications, blood transfusions and supplemental oxygen, as well as a bone marrow transplant.<br> | ||
* Immune-related [[hemolysis]] – [[corticosteroids]], [[folic acid]] is the main line of treatment<br> | *Immune-related [[hemolysis]] – [[corticosteroids]], [[folic acid]] is the main line of treatment<br> | ||
* Parasitic Infections like [[malaria]] are treated with [[antimalarial]] drugs like [[chloroquine]], [[artesunate]], [[lumefantrine]],[[amodiaquine]] <br> | *Parasitic Infections like [[malaria]] are treated with [[antimalarial]] drugs like [[chloroquine]], [[artesunate]], [[lumefantrine]],[[amodiaquine]] <br> | ||
* Ineffective erythropoiesis- iron and folic acid & B12 supplementation, repeated blood transfusions | *Ineffective erythropoiesis- iron and folic acid & B12 supplementation, repeated blood transfusions | ||
|- | |- | ||
|'''Managment of isolated unconjugated jaundice, Non-hemolytic''' || | |'''Managment of isolated unconjugated jaundice, Non-hemolytic'''|| | ||
*[[ Gilbert's syndrome]] does not produce symptoms or adverse effects and patients have a normal life span<br> | *[[ Gilbert's syndrome]] does not produce symptoms or adverse effects and patients have a normal life span<br> | ||
*[[Crigler-Najjar]] type I is fatal in early life due to development of [[kernicterus]].<br> | *[[Crigler-Najjar]] type I is fatal in early life due to development of [[kernicterus]].<br> | ||
*[[Crigler-Najjar]] type II is compatible with a normal life.| | *[[Crigler-Najjar]] type II is compatible with a normal life.| | ||
| | | | ||
* Phenobarbital can decrease serum bilirubin by enzymatic induction of UDPGT(Uridine [[Glucuronosyltransferase]]) in Crigler-Najjar type II. | *Phenobarbital can decrease serum bilirubin by enzymatic induction of UDPGT(Uridine [[Glucuronosyltransferase]]) in Crigler-Najjar type II. | ||
|- | |- | ||
|'''Managment of isolated conjugated jaundice''' || | |'''Managment of isolated conjugated jaundice'''|| | ||
*[[Dubin-Johnson syndrome]]- doesn't produce any symptoms and compatible with a normal life span.<br> | *[[Dubin-Johnson syndrome]]- doesn't produce any symptoms and compatible with a normal life span.<br> | ||
*[[Rotor's syndrome]] is a harmless chronic hyperbilirubinemia | | *[[Rotor's syndrome]] is a harmless chronic hyperbilirubinemia | | ||
| | | | ||
*Suspect for Dubin-Johnson syndrome before considering surgery if the healthy patient with long-standing [[conjugated]] [[hyperbilirubinemia]], other normal liver function tests, and a non visualized gallbladder.<br> | *Suspect for Dubin-Johnson syndrome before considering surgery if the healthy patient with long-standing [[conjugated]] [[hyperbilirubinemia]], other normal liver function tests, and a non visualized gallbladder.<br> | ||
* Hepatic architecture is normal but there is an accumulation of hepatic pigment compatible with [[melanin]] in patients with Dubin-Johnson syndrome<br> | *Hepatic architecture is normal but there is an accumulation of hepatic pigment compatible with [[melanin]] in patients with Dubin-Johnson syndrome<br> | ||
*In Rotor's syndrome the [[gallbladder]] opacifies normally with cholecystographic dye and no pigmentation be seen in the liver. | *In Rotor's syndrome the [[gallbladder]] opacifies normally with cholecystographic dye and no pigmentation be seen in the liver. | ||
|- | |- | ||
|'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈[[AST]]/[[ALT]] out of proportion to [[ALP]]'''' || | |'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈[[AST]]/[[ALT]] out of proportion to [[ALP]]''''|| | ||
*History of recent travel<br> | *History of recent travel<br> | ||
* Social history: Alcohol, sexual history<br> | *Social history: Alcohol, sexual history<br> | ||
* Family history of [[Wilson's disease]] or [[hemochromatosis]]<br> | *Family history of [[Wilson's disease]] or [[hemochromatosis]]<br> | ||
*Review medications<br> | *Review medications<br> | ||
*Pregnancy test<BR>[[HELLP syndrome]], [[AFLP]]<BR> | *Pregnancy test<BR>[[HELLP syndrome]], [[AFLP]]<BR> | ||
Line 192: | Line 197: | ||
*[[Viral hepatitis]]<br>Hepatitis A: mostly self-limiting <br> [[Hepatitis B]] treated with antiviral medications<br>[[Hepatitis C]] is treated with interferons<br>Other Viral infections like [[EBV]], [[CMV]], [[HSV]] are treated with Antiviral medications <br> | *[[Viral hepatitis]]<br>Hepatitis A: mostly self-limiting <br> [[Hepatitis B]] treated with antiviral medications<br>[[Hepatitis C]] is treated with interferons<br>Other Viral infections like [[EBV]], [[CMV]], [[HSV]] are treated with Antiviral medications <br> | ||
*[[Alcohol hepatitis]]: Alcohol abstinence, [[glucocorticoids]], [[pentoxifylline]]<br> | *[[Alcohol hepatitis]]: Alcohol abstinence, [[glucocorticoids]], [[pentoxifylline]]<br> | ||
* Wilson"s disease: chelating agents such as D-penicillamine<br> | *Wilson"s disease: chelating agents such as D-penicillamine<br> | ||
* Drug toxicity treatment(e.g. [[Acetaminophen]], [[Isoniazid]]<br> | *Drug toxicity treatment(e.g. [[Acetaminophen]], [[Isoniazid]]<br> | ||
* Autoimmune hepatitis treatment with glucocorticoids | *Autoimmune hepatitis treatment with glucocorticoids | ||
|- | |- | ||
|'''Managment of conjugated & unconjugated [[hyperbilirubinemia]] jaundice with ⇈ [[AlP]] out of proportion to [[AST]]/[[ALT]]'''|| | |'''Managment of conjugated & unconjugated [[hyperbilirubinemia]] jaundice with ⇈ [[AlP]] out of proportion to [[AST]]/[[ALT]]'''|| | ||
*History of intermittent right upper quadrant pain radiating to the back or right shoulder favors [[gallstones]], fever and chills suggest [[cholangitis]].<br> | *History of intermittent right upper quadrant pain radiating to the back or right shoulder favors [[gallstones]], fever and chills suggest [[cholangitis]].<br> | ||
* History of biliary tract surgery within 2 years should alert the physician to possible [[biliary]] stricture. <br> | *History of biliary tract surgery within 2 years should alert the physician to possible [[biliary]] stricture. <br> | ||
*History recent weight loss, constant epigastric or right upper quadrant pain radiating to the back suggests malignancy<br> | *History recent weight loss, constant epigastric or right upper quadrant pain radiating to the back suggests malignancy<br> | ||
*Icteric patient with extrahepatic obstruction due to gallstones or postsurgical biliary stricture has usually had acute symptoms for less than 2 weeks<br> | *Icteric patient with extrahepatic obstruction due to gallstones or postsurgical biliary stricture has usually had acute symptoms for less than 2 weeks<br> | ||
*Those with carcinoma, [[chronic pancreatitis]], or [[primary sclerosing cholangitis]] have had symptoms of longer duration<br> | *Those with carcinoma, [[chronic pancreatitis]], or [[primary sclerosing cholangitis]] have had symptoms of longer duration<br> | ||
* | *A middle-aged woman with a history of itching and autoimmune disease raises the suspicion of [[primary biliary cirrhosis]]<br>More than half the people with primary biliary cirrhosis do not have any symptoms when diagnosed. Symptoms develop over the next five to 20 years. Those who do have symptoms at diagnosis typically have poorer outcomes.<br> | ||
*Commonly used drugs such as [[antihypertensives]] (e.g., [[angiotensin-converting enzyme inhibitors]]) or [[hormones]] (e.g., estrogen) may cause [[cholestasis]]<br> | *Commonly used drugs such as [[antihypertensives]] (e.g., [[angiotensin-converting enzyme inhibitors]]) or [[hormones]] (e.g., estrogen) may cause [[cholestasis]]<br> | ||
*Abnormal [[ALP]] levels may be a sign of metastatic cancer of the liver, [[lymphoma]] or infiltrative diseases such as [[sarcoidosis]].<br> | *Abnormal [[ALP]] levels may be a sign of metastatic cancer of the liver, [[lymphoma]] or infiltrative diseases such as [[sarcoidosis]].<br> | ||
* History of inflammatory bowel disease (most commonly ulcerative colitis) suggests the presence of primary sclerosing cholangitis since about 70% of these cases are associated with inflammatory bowel disease<br> | *History of inflammatory bowel disease (most commonly ulcerative colitis) suggests the presence of primary sclerosing cholangitis since about 70% of these cases are associated with inflammatory bowel disease<br> | ||
*TPN is associated with ↑ [[AlP]] and [[GGT]] level.| | *TPN is associated with ↑ [[AlP]] and [[GGT]] level.| | ||
| | | | ||
Line 212: | Line 217: | ||
*Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. None of the medications has been found to slow or reverse the liver damage associated with this disease. | *Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. None of the medications has been found to slow or reverse the liver damage associated with this disease. | ||
|- | |- | ||
|'''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ↑ INR,↓ Alb,↓ PLT''' | | | '''Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ↑ INR,↓ Alb,↓ PLT''' | | ||
| | | | ||
*Cirrhotic patients with [[MELD]] Score> 15 should be referred to liver transplant center<br> | *Cirrhotic patients with [[MELD]] Score> 15 should be referred to liver transplant center<br> | ||
Line 218: | Line 223: | ||
| | | | ||
*Compensated Cirrhosis Mangament<br>Alochol abstinence<br> Antiviral medications for viral hepatitis<br> avoidance of hepatotoxic medications<br>vaccination<br> | *Compensated Cirrhosis Mangament<br>Alochol abstinence<br> Antiviral medications for viral hepatitis<br> avoidance of hepatotoxic medications<br>vaccination<br> | ||
*Decompensated Cirrhosis Managment<br>Managment of complications:<br>[[Varices]], [[Ascites]], [[Hepatorenal syndrome]], [[Hepatic encephalopathy]]( Acute liver failure ) | *Decompensated Cirrhosis Managment<br>Managment of complications:<br>[[Varices]], [[Ascites]], [[Hepatorenal syndrome]], [[Hepatic encephalopathy]]( Acute liver failure ) | ||
|- | |- | ||
|} | |} | ||
Line 224: | Line 229: | ||
==Do's== | ==Do's== | ||
* '''Alcohol Use''': Screen for alcohol use disorders in all patients | |||
* '''Medications''': Discuss the safety of limited (2 gram/day) acetaminophen use, review pharmacologic history, and discontinue medications that cause hemolysis or drug-induced hepatitis. | *'''[[Alcohol]] Use''': Screen for [[Alcohol abuse|alcohol use disorders]] in all [[patients]]. | ||
* Treat of underlying disease conditions | *'''Medications''': Discuss the safety of limited (2 gram/day) acetaminophen use, review pharmacologic history, and discontinue [[medications]] that cause [[hemolysis]] or drug-induced [[hepatitis]]. | ||
* Liver Transplant Referral: Refer early when a patient needs | *Treat of underlying disease [[conditions]]. | ||
* Palliative Care: Address goals of care and refer to palliative care early especially for patients with tumors | *[[Liver Transplant]] Referral: Refer early when a [[patient]] needs. | ||
*Palliative Care: Address goals of care and refer to palliative care early especially for [[patients]] with [[tumors]]. | |||
==Don'ts== | ==Don'ts== | ||
* Forget to discuss medication to avoid, especially in patients with [[G6PD]] or drug-induced hepatitis. | |||
* Delay palliative care until the patient is in a critical state. | *Forget to discuss [[medication]] to avoid, especially in [[patients]] with [[G6PD]] or drug-induced [[hepatitis]]. | ||
* Delay referring a patient to the liver transplant center until the patient is hospitalized in life-threatening condition | *Delay palliative care until the [[patient]] is in a critical state. | ||
*Delay referring a [[patient]] to the [[liver transplant]] center until the [[patient]] is hospitalized in life-threatening [[condition]]. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 17:21, 27 August 2020
Jaundice Resident Survival Guide |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Roghayeh Marandi, M.D.[2]
Synonyms and keywords: Approach to jaundice, Jaundice workup, Jaundice management
Overview
The classic definition of Jaundice is a serum bilirubin level higher than 2.5 to 3 mg per dL (42.8 to 51.3 μper L) in conjunction with a clinical picture of yellow skin and sclera. The causes of jaundice can be classified under these categories by measuring total bilirubin and its conjugated and unconjugated levels determine where is the dysfunction of bilirubin metabolism.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Ascending cholangitis
- Sepsis
- Acute liver failure (the combination of jaundice with hepatic encephalopathy)
Common Causes
Common causes of acute Jaundice[1]
- Gilbert syndrome
- Alcoholic hepatitis
- Viral hepatitis
- Obstructive Jaundice due to choledocholithiasis or malignancy
- Decompensated chronic liver disease
Common causes of chronic progressive jaundice
Diagnosis
Shown below is an algorithm summarizing the diagnosis of jaundice.[2][3][4][5]
Characterize the jaundice duration and frequency ❑Duration: short vs long ❑Frequency: episodic vesus constant | |||||||||||||||||||||||||||||||||||||||||||||||
Ask about associated symptoms ❑ Abdominal pain (episodic or constant) ❑ Abdominal distension ❑ Fever ❑ Clay colored stool ❑ Dark urine ❑ Weight gain or loss ❑ Anorexia ❑ Dyspepsia ❑ Arthralgia ❑ Myalgia ❑ Back pain ❑ Rash ❑ Confusion | |||||||||||||||||||||||||||||||||||||||||||||||
Inquire about ❑ Past medical history ❑ Blood disorder
❑ Family history of ❑ Medication history
❑ Recent travel history
| |||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient General Appearance ❑ Check for:
Skin exam
Cardiac exam
❑ Check gallbladder area if it is tender
❑ Splenomegaly can be seen in hemolytic states, Hodgkin’s lymphoma, portal hypertension
| |||||||||||||||||||||||||||||||||||||||||||||||
Order ❑ Blood tests
❑ Urine
| |||||||||||||||||||||||||||||||||||||||||||||||
Isolated unconjugated hyperbilirubinemia | Isolated conjugated hyperbilirubinemia | Unconjugated & conjugated hyperbilirubinemia | |||||||||||||||||||||||||||||||||||||||||||||
❑ Inquire about any recent trauma hematoma blood transfusion | ❑ Dubin-Johnson syndrome ❑ Rotor syndrome | ||||||||||||||||||||||||||||||||||||||||||||||
If none of them | With Liver enzyme changes | with ↑ INR,↓ Albumin,↓ Platelet | |||||||||||||||||||||||||||||||||||||||||||||
❑ Check Hb,LDH,Haptoglobin,Recticulocyte count | If ⇈AST/ALT out of proportion to ALP | If ⇈AlP out of proportion to AST/ALT | Suggestive of cCirrhosis Additional tests to find the cause of cirrhosis Hepatitis serology Iron panel Abdominal Ultrasound Workup for Automimmune hepatitis, NAFLD,Hemochromatosis & other causes of cirrhosis | ||||||||||||||||||||||||||||||||||||||||||||
Abnormal | Normal | Hepatocellular pattern | Cholestatic pattern | ||||||||||||||||||||||||||||||||||||||||||||
Start workup of hemolytic anemia with blood smear & coombs test | ❑ Gilbert syndrome ❑ Crigler-Najjar type I,II | Additional work-up for specific diseases Viral hepatitis serology(e.g. HAV,HBV,HCV) Toxicology screen Acetaminophen level Cereuloplasmin if patient<40 years of age Autoantibodies (ANA,Anti-sm,LKM,...) Ferritin & TIBC HbA1c Pregnancy test a1-antitrypsin ❑Consider work-up for rare cases Liver biopsy if results negative | Ultrasound | ||||||||||||||||||||||||||||||||||||||||||||
Consider following based on the results: ❑ Sickle cell disease ❑ Hereditary spherocytosis ❑ G6PD deficiency ❑ Medications effect( Rifampicin, Probencid) ❑ Immune-mediated hemolysis | Consider following based on the results: ❑ Viral hepatitis ❑ NAFLD (Non-alcoholic liver disease) ❑ ppAlcoholic liver disease]] ❑ Metabolic/genetic diseases Hereditary hemochromatosis Wilson's disease Alpha-1 antitrypsin deficiency ❑ Drug-induced and supplemental-induced injury Acetaminophen, kavakava, Vinyl cholride ❑ Pregnancy AFLP,HELLP syndrome ❑ Autoimmune hepatitis ❑ Ischemic hepatitis | Bile ducts dilated | Bile ducts not dilated | ||||||||||||||||||||||||||||||||||||||||||||
ERCP/CT | Additional work-up for intrahepatic cholestasis | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Common bile duct stones ❑ Biliray stricture ❑ Worms/flukes ❑ Extrahepatic sources: ❑ Cholangiocarcinoma ❑ Pancreatic cancer | Consider following based on the results: | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment
Type of hyperbilirubinemia | Diagnostic Indicators | Management Recommendations |
---|---|---|
Managment of isolated unconjugated jaundice, hemolytic |
|
|
Managment of isolated unconjugated jaundice, Non-hemolytic |
|
|
Managment of isolated conjugated jaundice |
|
|
Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈AST/ALT out of proportion to ALP' |
|
|
Managment of conjugated & unconjugated hyperbilirubinemia jaundice with ⇈ AlP out of proportion to AST/ALT |
|
|
|
Do's
- Alcohol Use: Screen for alcohol use disorders in all patients.
- Medications: Discuss the safety of limited (2 gram/day) acetaminophen use, review pharmacologic history, and discontinue medications that cause hemolysis or drug-induced hepatitis.
- Treat of underlying disease conditions.
- Liver Transplant Referral: Refer early when a patient needs.
- Palliative Care: Address goals of care and refer to palliative care early especially for patients with tumors.
Don'ts
- Forget to discuss medication to avoid, especially in patients with G6PD or drug-induced hepatitis.
- Delay palliative care until the patient is in a critical state.
- Delay referring a patient to the liver transplant center until the patient is hospitalized in life-threatening condition.
References
- ↑ Warner, Ben; Wilkinson, Mark (2017). "Acute jaundice": 150–154. doi:10.1002/9781119389613.ch23.
- ↑ Giannini EG, Testa R, Savarino V (February 2005). "Liver enzyme alteration: a guide for clinicians". CMAJ. 172 (3): 367–79. doi:10.1503/cmaj.1040752. PMC 545762. PMID 15684121.
- ↑ 3.0 3.1 Walker HK, Hall WD, Hurst JW, Stillman AE. PMID 21250253. Missing or empty
|title=
(help) - ↑ Gondal B, Aronsohn A (December 2016). "A Systematic Approach to Patients with Jaundice". Semin Intervent Radiol. 33 (4): 253–258. doi:10.1055/s-0036-1592331. PMC 5088098. PMID 27904243.
- ↑ Syhavong B, Rasachack B, Smythe L, Rolain JM, Roque-Afonso AM, Jenjaroen K, Soukkhaserm V, Phongmany S, Phetsouvanh R, Soukkhaserm S, Thammavong T, Mayxay M, Blacksell SD, Barnes E, Parola P, Dussaix E, Raoult D, Humphreys I, Klenerman P, White NJ, Newton PN (July 2010). "The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos". Trans. R. Soc. Trop. Med. Hyg. 104 (7): 475–83. doi:10.1016/j.trstmh.2010.03.002. PMC 2896487. PMID 20378138.
- ↑ Shroff H, Maddur H (April 2020). "Isolated Elevated Bilirubin". Clin Liver Dis (Hoboken). 15 (4): 153–156. doi:10.1002/cld.944. PMC 7206321 Check
|pmc=
value (help). PMID 32395242 Check|pmid=
value (help). - ↑ Garcia-Tsao G (February 2001). "Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis". Gastroenterology. 120 (3): 726–48. doi:10.1053/gast.2001.22580. PMID 11179247.
- ↑ McCullough AJ, O'Connor JF (November 1998). "Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology". Am. J. Gastroenterol. 93 (11): 2022–36. doi:10.1111/j.1572-0241.1998.00587.x. PMID 9820369.
- ↑ Baldwin C, Olarewaju O. PMID 32644330 Check
|pmid=
value (help). Missing or empty|title=
(help)